Related Experiment Video

Updated: Nov 23, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.7K

Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation

Michele Magnocavallo1, Antonio Bellasi2, Marco Valerio Mariani1

  • 1Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 155-00161 Rome, Italy.

Journal of Clinical Medicine
|December 31, 2020
PubMed

Insights

Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely linked, with AF affecting 15-20% of advanced CKD patients. This review explores direct oral anticoagulant (DOAC) use in CKD, particularly end-stage renal disease (ESRD), addressing current treatment limitations.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is highly prevalent in chronic kidney disease (CKD) patients, affecting 15-20% in advanced stages.
  • AF patients with end-stage renal disease (ESRD) face higher mortality due to increased stroke and bleeding risks.
  • Current anticoagulation with vitamin K antagonists (VKAs) in ESRD presents challenges like narrow therapeutic windows and unfavorable risk/benefit profiles.

Purpose of the Study:

  • To review the application and safety of direct oral anticoagulants (DOACs) in CKD patients.
  • To specifically examine DOAC therapy in end-stage renal disease (ESRD) populations.
  • To address the limitations of existing anticoagulation strategies in CKD and ESRD.

Main Methods:

  • Literature review of studies on AF, CKD, ESRD, DOACs, and VKAs.
  • Analysis of current guidelines and clinical trial data regarding anticoagulation in renal impairment.
  • Synthesis of evidence on the efficacy and safety of DOACs in CKD/ESRD patients.

Main Results:

  • Direct oral anticoagulants (DOACs) are generally contraindicated in ESRD.
  • Vitamin K antagonists (VKAs) are currently the only approved option for anticoagulation in ESRD but have significant drawbacks.
  • Limited data exists on DOAC use in CKD, with ongoing research into their potential role.

Conclusions:

  • There is a critical need for safer and more effective anticoagulation strategies for AF patients with CKD and ESRD.
  • Further research is required to establish the role and safety of DOACs in these patient populations.
  • Optimizing anticoagulation in CKD/ESRD is essential to reduce stroke and bleeding events and improve patient outcomes.

Keywords:
atrial fibrillationchronic kidney diseasedirect oral anticoagulantsend stage renal diseaseleft atrial appendage occlusionwarfarin

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.1K
Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
121
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
141
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
354
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
207